For patients with wet age-related macular degeneration (AMD) who have undergone years of frequent eye injections, a higher-dose treatment is offering a meaningful reprieve: longer stretches between appointments. A new real-world study found that switching to aflibercept 8 mg, a higher concentration of an existing drug, allowed heavily pre-treated patients to extend their treatment intervals while maintaining stable vision and eye health .

What Is Wet Macular Degeneration and Why Do Patients Need Frequent Injections?

Wet age-related macular degeneration is a progressive eye disease that damages the central part of the retina, the light-sensitive tissue at the back of the eye. Abnormal blood vessels grow beneath the retina and leak fluid, causing vision loss. Patients typically receive anti-VEGF (vascular endothelial growth factor) injections directly into the eye every 4 weeks to stop this abnormal vessel growth and preserve sight. Over months and years, this means dozens of injections, each requiring a trip to the ophthalmologist's office .

How Did the Study Measure Success for Treatment-Resistant Patients?

Researchers analyzed 58 patients (66 eyes total) who had already received an average of 25 anti-VEGF injections per eye over roughly four years before switching to the higher-dose aflibercept. The team tracked several key measures over six months: visual acuity (sharpness of sight), retinal thickness, fluid accumulation, and most importantly, how long patients could go between treatments .

The results showed meaningful progress for this challenging population. Median treatment intervals extended from 4 weeks at baseline to 6 weeks by the final visit, a statistically significant improvement. Even more striking, 35% of eyes achieved 8-week intervals by the end of follow-up, meaning these patients could go two months between injections instead of one .

Did Vision and Eye Structure Remain Stable?

One concern when switching treatments is whether patients might lose ground on vision or eye health. The study found reassuring stability across the board. Visual acuity remained unchanged, with a median of 70 ETDRS letters (a standard measure of eye chart performance) at both baseline and final follow-up. Central macular thickness, a measure of retinal swelling, also stayed stable at approximately 230 micrometers throughout the study period .

There was one anatomical improvement: pigment epithelial detachment (PED) height, a measure of fluid accumulation under the retina, showed a modest but statistically significant reduction. Additionally, complete fluid resolution occurred in nearly 24% of eyes that had baseline fluid present. No serious eye-related adverse events were reported in the cohort .

What Do These Findings Mean for Patients?

For patients who have exhausted standard treatment options or developed resistance to conventional anti-VEGF drugs, the ability to extend intervals between injections addresses a real quality-of-life concern. Fewer office visits mean less time away from work or family, reduced transportation burden, and lower cumulative exposure to the injection procedure itself. However, researchers emphasize that these are early, real-world results from a relatively small group observed over six months .

Steps to Discuss With Your Eye Doctor

• Treatment History Review: If you have been receiving frequent anti-VEGF injections for wet AMD with limited improvement, ask your ophthalmologist whether you might be a candidate for aflibercept 8 mg based on your specific disease pattern and response to prior treatments.
• Interval Goals: Discuss what treatment interval would meaningfully improve your quality of life. Even extending from 4 weeks to 6 weeks reduces office visits by 25% annually; achieving 8-week intervals cuts visits in half.
• Monitoring Plan: Clarify how frequently you will need imaging (optical coherence tomography scans) and eye exams if intervals are extended, since longer gaps between injections require closer monitoring to catch any disease progression early.
• Long-Term Durability: Ask whether your doctor has access to longer-term data beyond six months, since the current study is early-stage and researchers have called for extended follow-up to confirm durability.

What Questions Remain About This Treatment?

While the initial results are promising, important questions remain unanswered. The study was observational and relatively small, following only 66 eyes over a median of about 26 weeks. Researchers have not yet determined whether the interval extension persists beyond six months or whether some patients eventually develop resistance to the higher dose, as they did to standard-dose treatments. Additionally, long-term safety data in this heavily pre-treated population is still being collected .

The findings represent an important step forward for a subset of wet AMD patients who have limited options after years of conventional treatment. However, they underscore the need for larger, longer-term studies to establish whether aflibercept 8 mg can deliver sustained benefits and become a reliable option for treatment-resistant disease.